GSK Terminates Five-Year Cancer Partnership with Ideaya Biosciences, Returns Two Synthetic Lethality Programs
核心洞察
GSK has quietly terminated its synthetic lethality collaboration with Ideaya Biosciences, returning the last two assets IDE275 and IDE705 according to an SEC filing.
The termination follows GSK's earlier return of the MAT2A (搜索) inhibitor IDE397 in August 2022, marking the end of a partnership that began in June 2020 with $100 million upfront.
Ideaya will assess strategic options for the returned Werner helicase (搜索) inhibitor IDE275 and DNA Pol theta (搜索) inhibitor IDE705 in 2026, while maintaining its cash runway into 2030.
GSK has terminated its five-year synthetic lethality collaboration with Ideaya Biosciences, returning the final two cancer programs in the partnership and marking the end of what was once a promising alliance in precision oncology. The pharmaceutical giant informed Ideaya of its decision on December 4, with the discontinuation effective 90 days thereafter, according to an SEC filing revealed Friday.
The termination returns IDE275, a Werner helicase (搜索) inhibitor targeting solid tumors with high microsatellite instability, and IDE705, a DNA Pol theta (搜索) (polymerase θ) inhibitor designed for tumors with BRCA and other homologous recombination mutations. This follows GSK's earlier abandonment of the MAT2A (搜索) inhibitor IDE397 in August 2022, which Ideaya has continued to advance independently and has since delivered early clinical responses.
Partnership Background and Financial Terms
GSK first entered the collaboration in June 2020, paying $100 million upfront alongside a $20 million equity purchase of Ideaya's shares. The agreement also included unspecified preclinical, clinical and sales milestones. At the heart of the partnership was Ideaya's synthetic lethality approach to cancer, which targets specific combinations of genetic mutations that cancer cells cannot tolerate, creating vulnerabilities for treatment.
The original partnership focused on three programs—MAT2A (搜索), Pol Theta and Werner Helicase (搜索)—but GSK's progressive withdrawal from each asset suggests challenges in the synthetic lethality field that extend beyond this single collaboration.
Broader Market Challenges
The Werner helicase (搜索) inhibitor field has faced significant skepticism following disappointing developments across the industry. Roche previously handed its Werner inhibitor RO7589831 back to Vividion (搜索), while Novartis presented underwhelming data with HRO761 at this year's ESMO conference.
Similarly, the Pol theta inhibitor landscape has encountered challenges. Artios (搜索) remains the only company to report clinical results to date, but activity with its candidate ART6043 appeared only when combined with Lynparza, suggesting the need for combination approaches rather than monotherapy efficacy.
Ideaya's Strategic Response
Despite losing its powerhouse partner, Ideaya appears confident in its ability to move forward independently. The company noted in its SEC filing that the termination "does not change the expectation of cash runway into 2030." As of September 30, the biotech maintained approximately $1.14 billion in cash, cash equivalents and marketable securities, according to its Q3 report.
Ideaya plans to assess "strategic options" for IDE275 and IDE705 in 2026, though the future for both modalities remains uncertain. According to analysts at Truist Securities, these options could include "seeking new partners or advancing the assets internally," with the decision ultimately depending on "emerging data across the treatment landscape."
Focus on Lead Program
Analysts at Truist called the development "disappointing" but noted they "do not view this update as thesis-changing" for Ideaya's pipeline. The company's lead value driver remains darovasertib, a small-molecule kinase blocker for uveal melanoma (搜索), with Phase II/III data expected by year-end or early next year.
The termination comes as GSK's cancer business secured a surprising comeback with Blenrep in October, winning FDA approval for third-line multiple myeloma (搜索) despite a negative vote from the regulator's external advisors. Meanwhile, GSK struck another early-stage deal this week with Oxford Biotherapeutics (搜索), though no details were provided about projects, targets, or financial terms.